Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ME3 | Q16798 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22868465 | 0.88 | EPHX2 (0.56) | EPHX2SIGMAR1 | |
| SCHEMBL21514108 | 0.85 | EPHX2 (0.61) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL10211633 | 0.85 | SIGMAR1 (0.60) | EPHX2SIGMAR1ALDH1A1 | |
| SCHEMBL13847101 | 0.82 | SIGMAR1 (0.72) | EPHX2SIGMAR1MEN1KMT2AME3 | |
| SCHEMBL10212124 | 0.81 | NPC1 (0.68) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL13621159 | 0.81 | SIGMAR1 (0.58) | SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL5049597 | 0.80 | EPHX2 (0.90) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2753089 | 0.80 | EPHX2 (0.96) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4356360 | 0.80 | CTSL (0.57) | MEN1KMT2AUSP30 | |
| SCHEMBL10210847 | 0.80 | CTSL (0.57) | MEN1KMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | EPHX2 3440/4885SIGMAR1 4493/4885MEN1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.